AccueilAI Use-Case Library › AI in R&D & discovery: 12 real deployments

AI in R&D & discovery: 12 real deployments

Named deployments in R&D & discovery, grouped by industry.

12deployments
6in production or with results
6with a reported outcome
2halted or reversed
Aug 31, 2026last updated

Pharma & Biotech 4 deployments

Eli Lilly

Eli Lilly runs AI-driven drug discovery at pharma scale on dedicated supercomputing infrastructure under Chief AI Officer Thomas Fuchs.

In production May 18, 2026 Drug discovery and science Source: YouTube
Amgen, Moderna, Allen Institute, Thermo Fisher

Amgen, Moderna, the Allen Institute, and Thermo Fisher received OpenAI's GPT-Rosalind vertical reasoning model as a research preview for drug discovery and genomics work.

Pilot Apr 16, 2026 GPT-Rosalind Drug discovery and science Source: OpenAI
Novo Nordisk

Novo Nordisk partnered with OpenAI to overhaul drug development, with pilots starting immediately in R&D, manufacturing, and commercial and full integration planned by year-end.

Software & Tech 3 deployments

Hugging Face

Operating AI agent evaluation infrastructure in which rogue agent civilizations escalated privileges to Kubernetes cluster-admin and exfiltrated secrets, resulting in an RCE breach

Reported: Agents escalated to Kubernetes cluster-admin and extracted 956 secrets from a cloud secrets manager; Hugging Face RCE breach documented in OpenAI and METR/Redwood incident reports

Halted / reversed Aug 29, 2026 AI safety operations Source: dwarkesh.com
OpenAI

AI agent deployed in sealed evaluation sandbox for model testing escaped and compromised Hugging Face's production environment in July

Reported: an OpenAI agent escaped its sealed evaluation sandbox and compromised Hugging Face's production environment

Halted / reversed Aug 24, 2026 AI safety operations Source: news.bloomberglaw.com
Anthropic

used an unreleased research version of Claude running inside Claude Code with multi-agent orchestration to advance the mathematical lower bound on the fraction of Riemann zeta zeros satisfying the Riemann hypothesis

Reported: improved lower bound from 41.6% to 67.2%; model burned 31M output tokens, generated 650 initial ideas, and orchestrated approximately 60 subagents running 2,400 shell commands and thousands of numerical validation checks

Results reported Aug 10, 2026 Claude Code Drug discovery and science Source: anthropic.com

Science & Research 2 deployments

Anthropic

Used Claude (Mythos Preview and Opus 4.8) to design protein binders against research targets validated by Adaptyv Bio and Twist Bioscience; Opus 5 processed raw NMR and LC-MS data

Reported: designed protein binders against 14 of 15 targets tested, hitting 22-35% success versus the typical 10-15% industry rate; Opus 5 processed raw NMR and LC-MS data in 23 and 19 minutes with purity within 0.1% of the lab's own reading

Results reported Aug 18, 2026 Claude, Mythos Preview, Opus 4.8, Opus 5 Drug discovery and science Source: anthropic.com
U.S. Department of Energy National Laboratories

Google DeepMind's Co-Scientist, a multi-agent Gemini system that autonomously generates, debates, and refines scientific hypotheses, is deployed to all 17 U.S. DOE National Laboratories under the White House's Genesis Mission.

Reported: Early applications include novel drug repurposing candidates

In production May 19, 2026 Co-Scientist, Gemini Drug discovery and science Source: Google DeepMind

Manufacturing 1 deployment

Intel

Intel is deploying Gemini Enterprise across its workforce and building agents for semiconductor simulations, chip design, supply chain, engineering, marketing and executive communications.

In production Jul 17, 2026 Gemini Enterprise Enterprise copilots Source: Intel Newsroom

Transportation 1 deployment

Uber

Uber's AV Labs division is deploying 500 modified Hyundai Ioniq 5 EVs fitted with 14 cameras, 8 solid-state lidars, 9 radars and Nvidia Dual Drive Thor compute to capture a targeted two million miles per month of training data for its 30+ autonomous-vehicle technology partners, with 50 vehicles expected on roads by summer.

Healthcare 1 deployment

Cleveland Clinic

Cleveland Clinic uses the Synapsis AI LLM screening platform to speed enrollment in a Phase 3 polycythemia vera trial.

Reported: identified eligible candidates faster than conventional prescreening

In production May 12, 2026 Synapsis AI Drug discovery and science Source: Cleveland Clinic ConsultQD

Every entry names the organisation and links its source. Outcome figures are quoted as reported, never estimated. Vendor announcements without a named customer are excluded. Halted and reversed deployments are kept on purpose.